​

Jazz Pharmaceuticals (JAZZ) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

JAZZ Stock Forecast

Jazz Pharmaceuticals (JAZZ) stock forecast, based on 46 Wall Street analysts, predicts a 12-month average price target of $186.20, with a high of $230.00 and a low of $160.00. This represents a 83.36% increase from the last price of $101.55.

$100 $130 $160 $190 $220 $250 High: $230 Avg: $186.2 Low: $160 Last Closed Price: $101.55

JAZZ Stock Rating

Jazz Pharmaceuticals stock's rating consensus is Buy, based on 46 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 41 Buy (89.13%), 5 Hold (10.87%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 46 0 5 41 Strong Sell Sell Hold Buy Strong Buy

JAZZ Price Target Upside V Benchmarks

TypeNameUpside
StockJazz Pharmaceuticals83.36%
SectorHealthcare Stocks 33.91%
IndustryBiotech Stocks 83.49%
IdeaCannabis Stocks List300.67%

Price Target Trends

1M3M12M
# Anlaysts-28
Avg Price Target-$215.00$188.25
Last Closing Price$101.55$101.55$101.55
Upside/Downside-111.72%85.38%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25892--19
Mar, 25983--20
Feb, 25983--20
Jan, 25983--20
Dec, 24984--21
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 06, 2025Truist Financial$230.00$136.4568.56%126.49%
Feb 27, 2025Balaji PrasadBarclays$200.00$144.1738.73%96.95%
Nov 21, 2024Akash TewarJefferies$160.00$125.1027.90%57.56%
Nov 18, 2024Joel BeattyRobert W. Baird$162.00$122.0032.79%59.53%
Oct 23, 2024Daniel BusbRBC Capital$179.00$113.1058.27%76.27%
Sep 11, 2024Annabel SamimyStifel Nicolaus$230.00$105.22118.59%126.49%
Jun 05, 2024Andrea TanGoldman Sachs$169.00$104.4861.75%66.42%
May 02, 2024Daniel BusbRBC Capital$176.00$110.3159.55%73.31%
Mar 20, 2024David AmsellemPiper Sandler$188.00$124.7950.65%85.13%
Dec 09, 2022Goldman Sachs$190.00$150.0726.61%87.10%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 07, 2025UBSUnderperformBuyupgrade
Feb 27, 2025BarclaysOverweightOverweighthold
Nov 21, 2024JefferiesBuyBuyhold
Oct 23, 2024RBC CapitalOutperformOutperformhold
Oct 04, 2024Wells FargoBuyBuyhold
Sep 09, 2024Wells FargoBuyBuyhold
Aug 23, 2024Cowen & Co.BuyBuyhold
Aug 01, 2024Wells FargoBuyBuyhold
Jul 02, 2024UBSBuyBuyhold
Jun 06, 2024RBC CapitalOutperformOutperformhold

Financial Forecast

EPS Forecast

$-10 $-1 $8 $17 $26 $35 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$4.28$-5.51$-3.42$6.95$9.06----
Avg Forecast$12.60$15.67$13.56$18.50$20.21$21.88$22.40$25.00$26.78
High Forecast$13.20$16.42$14.21$18.73$20.49$23.81$26.66$31.99$28.52
Low Forecast$11.91$14.81$12.76$18.16$19.74$19.59$16.18$14.90$25.04
Surprise %-66.03%-135.16%-125.22%-62.43%-55.17%----

Revenue Forecast

$2B $3B $3B $4B $5B $6B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$2.36B$3.09B$3.66B$3.83B$4.07B----
Avg Forecast$2.33B$3.06B$3.66B$3.83B$4.04B$4.31B$4.48B$4.76B$5.04B
High Forecast$2.42B$3.18B$3.79B$3.93B$4.06B$4.53B$4.49B$4.78B$5.30B
Low Forecast$2.23B$2.93B$3.49B$3.78B$4.01B$4.10B$4.46B$4.73B$4.79B
Surprise %1.37%1.04%0.00%0.02%0.76%----

Net Income Forecast

$-500M $100M $700M $1B $2B $3B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$238.62M$-328.95M$-214.14M$414.83M$560.12M----
Avg Forecast$162.64M$1.13B$177.38M$414.83M$1.45B$1.56B$1.54B$1.69B$1.93B
High Forecast$279.03M$1.18B$226.81M$530.42M$1.48B$1.72B$1.92B$2.31B$2.06B
Low Forecast$46.25M$1.07B$127.96M$299.25M$1.42B$1.41B$1.17B$1.07B$1.80B
Surprise %46.72%-129.13%-220.72%--61.36%----

JAZZ Forecast FAQ

Is Jazz Pharmaceuticals stock a buy?

Jazz Pharmaceuticals stock has a consensus rating of Buy, based on 46 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 41 Buy, 5 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Jazz Pharmaceuticals is a favorable investment for most analysts.

What is Jazz Pharmaceuticals's price target?

Jazz Pharmaceuticals's price target, set by 46 Wall Street analysts, averages $186.2 over the next 12 months. The price target range spans from $160 at the low end to $230 at the high end, suggesting a potential 83.36% change from the previous closing price of $101.55.

How does Jazz Pharmaceuticals stock forecast compare to its benchmarks?

Jazz Pharmaceuticals's stock forecast shows a 83.36% upside, outperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the biotech stocks industry (83.49%), trailing the Cannabis Stocks List (300.67%) investment idea.

What is the breakdown of analyst ratings for Jazz Pharmaceuticals over the past three months?

  • April 2025: 42.11% Strong Buy, 47.37% Buy, 10.53% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 45.00% Strong Buy, 40.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 45.00% Strong Buy, 40.00% Buy, 15.00% Hold, 0% Sell, 0% Strong Sell.

What is Jazz Pharmaceuticals’s EPS forecast?

Jazz Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2025 is $21.88, marking a 141.50% increase from the reported $9.06 in 2024. Estimates for the following years are $22.4 in 2026, $25 in 2027, and $26.78 in 2028.

What is Jazz Pharmaceuticals’s revenue forecast?

Jazz Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2025 is $4.31B, reflecting a 5.92% increase from the reported $4.07B in 2024. The forecast for 2026 is $4.48B, followed by $4.76B for 2027, and $5.04B for 2028.

What is Jazz Pharmaceuticals’s net income forecast?

Jazz Pharmaceuticals's net income forecast for the fiscal year ending in December 2025 stands at $1.56B, representing an 179.23% increase from the reported $560.12M in 2024. Projections indicate $1.54B in 2026, $1.69B in 2027, and $1.93B in 2028.